Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
Tabla de Políticas Médicas
| ID | Título | Revisión | Descripción | Acceso |
|---|---|---|---|---|
| 02.002.016 | Cardiac Hemodynamic Monitoring For The Management Of Heart Failure In The Outpatient Setting | Jun 2026 | A variety of outpatient cardiac hemodynamic monitoring devices are intended to improve quality of life and... | Ver |
| 02.002.038 | Intravascular Lithotripsy | Aug 2026 | Intravascular lithotripsy (ivl) delivers unfocused, circumferential, pulsatile mechanical energy to safely... | Ver |
| 07.001.151 | Prostatic Urethral Lift | Sep 2025 | Benign prostatic hyperplasia (bph) is a common condition in older individuals that can lead to increased... | Ver |
| 10.001.014 | TELEMEDICINE | Aug 2026 | Telemedicine is the remote exchange of medical information through secure electronic communication to support... | Ver |
| M3.001.001 | Therapeutic Radiopharmaceuticals for Prostate Cancer | Aug 2026 | ... | Ver |
| M5.001.020 | Givosiran for Acute Hepatic Porphyria | May 2026 | Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... | Ver |
| M5.001.021 | Biological Treatments for Refractory Myasthenia Gravis | Jul 2026 | Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... | Ver |
| M5.001.022 | Ultomiris® (ravulizumab-cwvz) | May 2026 | Ravulizumab-cwvz is a complement inhibitor indicated as a treatment for adult patients, 18 years and older,... | Ver |
| M5.001.024 | Adstiladrin® (nadofaragene firadenovec-vncg) | Jun 2026 | Adstiladrin is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult... | Ver |
| M7.001.001 | Laser Treatment of Wine Stains | May 2024 | Studies have generally found that laser treatment can be effective at lightening port wine stains. the... | Ver |
| MP.001.001 | Dose rounding of drugs covered under the Medical Benefit | May 2026 | ... | Ver |
| MP.001.002 | Leuprolide | May 2024 | (leuprolide acetate) – a drug that is a manufactured version of a hormone. it is a hormone-releasing... | Ver |
| PP.001.001 | Dose Rounding of Drug Covered Under The Medical Benefit | May 2026 | ... | Ver |
| PP.001.002 | Leuprolide | May 2026 | (leuprolide acetate) – a drug that is a manufactured version of a hormone. it is a hormone-releasing... | Ver |
| PP.001.004 | Coverage Guideline for Orphan Drugs and Off-Label and Labeled Use of FDA Approved Drugs | Jan 2026 | Triple s salud has a procedure designed to ensure the evaluation of requests for coverage of covered... | Ver |